Skocz do pozycji: 1.

Tytuł:

HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer.

Autorzy:

Suo D; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Gao X; The clinical Laboratory Center, Hainan General Hospital, Hainan affiliated Hospital of Hainan Medical University, Haikou, 570311, China.
Chen Q; Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Zeng T; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Zhan J; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Li G; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Zheng Y; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Zhu S; The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Yun J; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Guan XY; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.; Department of Clinical Oncology, The University of Hongkong, Hong Kong, China.
Li Y; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China. .

Pokaż więcej

Źródło:

Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Apr 08; Vol. 43 (1), pp. 106. Date of Electronic Publication: 2024 Apr 08.

Typ publikacji:

Journal Article

MeSH Terms:

CD8-Positive T-Lymphocytes*/metabolism
Stomach Neoplasms*/genetics
Stomach Neoplasms*/metabolism
Humans ; Up-Regulation ; Immune Evasion ; Drug Therapy, Combination ; HSP110 Heat-Shock Proteins/metabolism ; AlkB Homolog 5, RNA Demethylase/metabolism

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 2.

Tytuł:

Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry.

Autorzy:

Dai C; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Liu M; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Yang Z; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Li Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Zhou Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Lu D; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Xia Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Chen A; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Li C; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Lu H; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Dai Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Ma J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Chen Z; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China. .; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .
Qian J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China. .; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .
Ge J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China. .; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .

Pokaż więcej

Źródło:

BMC medicine [BMC Med] 2024 Apr 02; Vol. 22 (1), pp. 148. Date of Electronic Publication: 2024 Apr 02.

Typ publikacji:

Clinical Trial; Journal Article

MeSH Terms:

Acute Coronary Syndrome*/drug therapy
Acute Coronary Syndrome*/surgery
Isoindoles*
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/methods
Phenylbutyrates*
Humans ; Aspirin/adverse effects ; Drug Therapy, Combination ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Platelet Aggregation Inhibitors/adverse effects ; Registries ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 3.

Tytuł:

MFSynDCP: multi-source feature collaborative interactive learning for drug combination synergy prediction.

Autorzy:

Dong Y; School of Software, Taiyuan University of Technology, Taiyuan, Shanxi, China. .
Chang Y; School of Software, Taiyuan University of Technology, Taiyuan, Shanxi, China.
Wang Y; School of Software, Taiyuan University of Technology, Taiyuan, Shanxi, China.
Han Q; School of Software, Taiyuan University of Technology, Taiyuan, Shanxi, China.
Wen X; School of Software, Taiyuan University of Technology, Taiyuan, Shanxi, China.
Yang Z; School of Software, Taiyuan University of Technology, Taiyuan, Shanxi, China.
Zhang Y; School of Software, Taiyuan University of Technology, Taiyuan, Shanxi, China.
Qiang Y; College of Computer Science and Technology (College of Data Science), Taiyuan University of Technology, Taiyuan, Shanxi, China. .
Wu K; School of Computing, University of Leeds, Leeds, West Yorkshire, UK.
Fan X; Information Management Department, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China.
Ren X; Information Management Department, Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China.

Pokaż więcej

Źródło:

BMC bioinformatics [BMC Bioinformatics] 2024 Apr 01; Vol. 25 (1), pp. 140. Date of Electronic Publication: 2024 Apr 01.

Typ publikacji:

Journal Article

MeSH Terms:

Benchmarking*
Simulation Training*
Drug Combinations ; Drug Therapy, Combination ; Cell Line

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 4.

Tytuł:

Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease.

Autorzy:

Marmor M; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America. .
Sharifi H; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Jacobs S; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Fazeli K; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Ruoss S; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.

Pokaż więcej

Źródło:

Respiratory research [Respir Res] 2024 Mar 11; Vol. 25 (1), pp. 123. Date of Electronic Publication: 2024 Mar 11.

Typ publikacji:

Review; Journal Article

MeSH Terms:

Mycobacterium avium-intracellulare Infection*/diagnosis
Mycobacterium avium-intracellulare Infection*/drug therapy
Mycobacterium avium-intracellulare Infection*/microbiology
Lung Diseases*/diagnosis
Lung Diseases*/drug therapy
Lung Diseases*/epidemiology
Liver Diseases*
Humans ; Mycobacterium avium Complex ; Retrospective Studies ; Drug Therapy, Combination ; Anti-Bacterial Agents/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 5.

Tytuł:

Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.

Autorzy:

Lim SY; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lee J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Osuna CE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Vikhe P; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Schalk DR; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Chen E; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Fray E; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Kumar M; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Schultz-Darken N; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Rakasz E; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Capuano S; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Ladd RA; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Gil HM; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Evans DT; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Jeng EK; Altor Biosciences, Miramar, FL 33027, USA.
Seaman M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Martin M; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Van Dorp C; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Perelson AS; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.; Santa Fe Institute, Santa Fe, NM 87501, USA.
Wong HC; Altor Biosciences, Miramar, FL 33027, USA.
Siliciano JD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Siliciano R; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Safrit JT; ImmunityBio, Culver City, CA 90232, USA.
Nixon DF; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Soon-Shiong P; ImmunityBio, Culver City, CA 90232, USA.
Nussenzweig M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.
Whitney JB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.; Department of Biology, Boston College, Chestnut Hill, MA 02467, USA.

Pokaż więcej

Źródło:

Science (New York, N.Y.) [Science] 2024 Mar 08; Vol. 383 (6687), pp. 1104-1111. Date of Electronic Publication: 2024 Feb 29.

Typ publikacji:

Journal Article

MeSH Terms:

Anti-Retroviral Agents*/therapeutic use
Anti-Retroviral Agents*/pharmacology
Simian Acquired Immunodeficiency Syndrome*/drug therapy
Simian Acquired Immunodeficiency Syndrome*/therapy
Simian Immunodeficiency Virus*
Recombinant Fusion Proteins*/administration & dosage
Recombinant Fusion Proteins*/pharmacology
Animals ; Humans ; Broadly Neutralizing Antibodies/administration & dosage ; CD8-Positive T-Lymphocytes/virology ; Immunotherapy ; Macaca mulatta ; Viral Load ; Remission Induction ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 6.

Tytuł:

The prevalence, clinical reasoning and impact of non-standard anti-tuberculosis regimens at the initial prescription.

Autorzy:

Chen RT; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
Liu CY; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
Lin SY; College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, No 7, Chung Shan South Road, Taipei, Taiwan.
Shu CC; College of Medicine, National Taiwan University, Taipei, Taiwan. .; Department of Internal Medicine, National Taiwan University Hospital, No 7, Chung Shan South Road, Taipei, Taiwan. .
Sheng WH; College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, No 7, Chung Shan South Road, Taipei, Taiwan.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Mar 07; Vol. 14 (1), pp. 5631. Date of Electronic Publication: 2024 Mar 07.

Typ publikacji:

Journal Article

MeSH Terms:

Tuberculosis*/drug therapy
Tuberculosis*/epidemiology
Tuberculosis, Multidrug-Resistant*/drug therapy
Gout*/drug therapy
Humans ; Antitubercular Agents/therapeutic use ; Prevalence ; Drug Therapy, Combination ; Clinical Reasoning

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 7.

Tytuł:

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes.

Autorzy:

Ali RA; Zoology Department, Faculty of Science, South Valley University, Qena, Egypt.
Awadalla EA; Zoology Department, Faculty of Science, Aswan University, Aswan, Egypt.
Amin YA; Department of Theriogenology, Faculty of Veterinary Medicine, Aswan University, Aswan, Egypt. .
Fouad SS; Qena University Hospital, South Valley University, Qena, Egypt.
Ahmed MAB; Department of Anatomy, Faculty of Medicine, South Valley University, Qena, Egypt.
Hassan MH; Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt.
Abdel-Kahaar E; Department of Medical Pharmacology, Faculty of Medicine, South Valley University, Qena, Egypt.; Institute of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg, Germany.
Abdel-Aziz RH; Department of Medical Physiology, Faculty of Medicine, South Valley University, Qena, Egypt.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Mar 07; Vol. 14 (1), pp. 5682. Date of Electronic Publication: 2024 Mar 07.

Typ publikacji:

Journal Article

MeSH Terms:

Hepatitis C, Chronic*/drug therapy
Pancreatitis*/chemically induced
Humans ; Adult ; Child ; Male ; Animals ; Rats ; Antiviral Agents/adverse effects ; Sofosbuvir/adverse effects ; Ribavirin/therapeutic use ; Hepacivirus/genetics ; Acute Disease ; Treatment Outcome ; Drug Therapy, Combination ; Semen ; Sperm Motility ; Liver Cirrhosis/complications ; Lipase/genetics ; Genotype

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 8.

Tytuł:

Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies.

Autorzy:

Underwood M; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Urbaityte R; GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Wang R; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Horton J; Parexel, 2520 Meridian Parkway, Durham, NC 27713, USA.
Oyee J; GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Wynne B; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Fox D; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Jones B; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Man C; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Sievers J; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.

Pokaż więcej

Źródło:

Viruses [Viruses] 2024 Mar 06; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 06.

Typ publikacji:

Journal Article

MeSH Terms:

HIV Infections*/drug therapy
Anti-HIV Agents*/therapeutic use
HIV-1*
HIV Seropositivity*
Oxazines*
Piperazines*
Pyridones*
Adult ; Humans ; Lamivudine/therapeutic use ; Emtricitabine/therapeutic use ; Tenofovir/therapeutic use ; Drug Therapy, Combination ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Viral Load ; Virus Replication

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 9.

Tytuł:

Efficacy and safety of venlafaxine hydrochloride combined with tandospirone citrate for patients with vascular depression accompanied by somatic symptoms: An open-labeled randomized control trial.

Autorzy:

Chen H; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Lin Y; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.; Department of Neurology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, China.
Zhao Z; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Lin T; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Lin Q; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Chen X; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Wu W; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Zeng G; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Wu S; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Liu N; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Chen H; Gynecology Department, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Chen R; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Xiao Y; Department of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.

Pokaż więcej

Źródło:

CNS neuroscience & therapeutics [CNS Neurosci Ther] 2024 Mar; Vol. 30 (3), pp. e14650.

Typ publikacji:

Journal Article; Randomized Controlled Trial

MeSH Terms:

Anti-Anxiety Agents*
Isoindoles*
Medically Unexplained Symptoms*
Piperazines*
Pyrimidines*
Vascular Depression*
Humans ; Citrates ; Depression/drug therapy ; Selective Serotonin Reuptake Inhibitors ; Serotonin ; Treatment Outcome ; Venlafaxine Hydrochloride/therapeutic use ; Drug Therapy, Combination/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 10.

Tytuł:

Clinical outcomes and risk factors for immune recovery and all-cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study.

Autorzy:

Castillo-Rozas G; Laboratory of Molecular and Cellular Virology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.; HIV/AIDS Workgroup, Faculty of Medicine, University of Chile, Santiago, Chile.
Tu S; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Luz PM; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Mejia F; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú.
Sierra-Madero J; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
Rouzier V; Groupe Haitien d'Etudes du Sarcome de Kaposi et des Infections Opportunistes, Port-au-Prince, Haiti.
Shepherd BE; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Cortes CP; HIV/AIDS Workgroup, Faculty of Medicine, University of Chile, Santiago, Chile.; Department of Internal Medicine, Faculty of Medicine, University of Chile, Santiago, Chile.; Hospital Clínico San Borja Arriarán & Fundación Arriarán, Santiago, Chile.; Millenium Institute on Immunology and Immunotherapy, Santiago, Chile.

Pokaż więcej

Źródło:

Journal of the International AIDS Society [J Int AIDS Soc] 2024 Mar; Vol. 27 (3), pp. e26214.

Typ publikacji:

Journal Article

MeSH Terms:

HIV Infections*
Acquired Immunodeficiency Syndrome*/drug therapy
Anti-HIV Agents*/therapeutic use
Humans ; Male ; Retrospective Studies ; Risk Factors ; Drug Therapy, Combination ; CD4 Lymphocyte Count ; Viral Load ; Antiretroviral Therapy, Highly Active

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 11.

Tytuł:

Clopidogrel with indobufen or aspirin in minor ischemic stroke or high-risk transient ischemic attack: a randomized controlled clinical study.

Autorzy:

Liu X; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Lv X; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Peng Y; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Wang J; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Lei J; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Tang C; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Luo S; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Mai W; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Cai Y; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Fan Q; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Liu C; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Zhang L; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China. .

Pokaż więcej

Źródło:

BMC neurology [BMC Neurol] 2024 Mar 01; Vol. 24 (1), pp. 81. Date of Electronic Publication: 2024 Mar 01.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Ischemic Attack, Transient*/drug therapy
Ischemic Attack, Transient*/epidemiology
Ischemic Stroke*/drug therapy
Stroke*/drug therapy
Phenylbutyrates*
Isoindoles*
Humans ; Aspirin ; Clopidogrel/therapeutic use ; Platelet Aggregation Inhibitors/adverse effects ; Prospective Studies ; Hemorrhage/chemically induced ; Drug Therapy, Combination ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 12.

Tytuł:

Efficacy and tolerability of adjunctive lacosamide in patients aged <4 years with focal seizures.

Autorzy:

Makedonska I; Municipal Non-profit Enterprise City Children's Clinical Hospital #6 of Dnipro City Council, Dnipro, Ukraine.
Ng YT; Baylor College of Medicine/The Children's Hospital of San Antonio, San Antonio, Texas, USA.
Beller C; UCB Pharma, Morrisville, North Carolina, USA.
Bozorg A; UCB Pharma, Morrisville, North Carolina, USA.
Csikós J; UCB Pharma, Monheim am Rhein, Germany.
McClung C; UCB Pharma, Morrisville, North Carolina, USA.
Moeltgen H; UCB Pharma, Monheim am Rhein, Germany.
Farkas MK; Pediatric Center, MTA Center of Excellence, Semmelweis University, Budapest, Hungary.

Pokaż więcej

Corporate Authors:

SP0967 Study Group

Źródło:

Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2024 Mar; Vol. 11 (3), pp. 768-779. Date of Electronic Publication: 2024 Feb 20.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Anticonvulsants*/adverse effects
Epilepsies, Partial*/drug therapy
Adult ; Child ; Humans ; Child, Preschool ; Lacosamide/adverse effects ; Reproducibility of Results ; Acetamides/adverse effects ; Drug Therapy, Combination ; Dose-Response Relationship, Drug ; Treatment Outcome ; Seizures/drug therapy ; Seizures/chemically induced

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 13.

Tytuł:

Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

Autorzy:

Kishi T; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Sakuma K; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Hatano M; Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Matsuda Y; Department of Psychiatry, Jikei University School of Medicine, Minato, Tokyo, Japan.
Esumi S; Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Hyogo, Japan.
Miyake N; Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Miura I; Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hori H; Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Kato M; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Iwata N; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.

Pokaż więcej

Źródło:

Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 216-220. Date of Electronic Publication: 2023 Aug 30.

Typ publikacji:

Meta-Analysis; Systematic Review; Journal Article

MeSH Terms:

Depressive Disorder, Major*/drug therapy
Adult ; Humans ; Japan ; Antidepressive Agents/therapeutic use ; Drug Therapy, Combination ; Randomized Controlled Trials as Topic

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 14.

Tytuł:

Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.

Autorzy:

Zandifar A; Social Determinants of Health Research Center, Alborz University of Medical Sciences, Karaj, Iran.; Department of Psychiatry, Imam Hossein Hospital, Alborz University of Medical Sciences, Karaj, Alborz, Iran.
Panahi M; Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Badrfam R; Department of Psychiatry, Imam Hossein Hospital, Alborz University of Medical Sciences, Karaj, Alborz, Iran. .
Qorbani M; Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.; Chronic Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

Pokaż więcej

Źródło:

BMC psychiatry [BMC Psychiatry] 2024 Feb 26; Vol. 24 (1), pp. 163. Date of Electronic Publication: 2024 Feb 26.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Benzhydryl Compounds*
Citalopram*/therapeutic use
Depressive Disorder, Major*/drug therapy
Glucosides*
Humans ; Antidepressive Agents/therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Treatment Outcome ; Adolescent ; Young Adult ; Adult ; Middle Aged

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 15.

Tytuł:

The Role of Cilostazol, a Phosphodiesterase-3 Inhibitor, in the Development of Atherosclerosis and Vascular Biology: A Review with Meta-Analysis.

Autorzy:

Sohn M; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea.
Lim S; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2024 Feb 23; Vol. 25 (5). Date of Electronic Publication: 2024 Feb 23.

Typ publikacji:

Meta-Analysis; Journal Article; Review

MeSH Terms:

Atherosclerosis*
Peripheral Arterial Disease*
Humans ; Cilostazol ; Phosphodiesterase 3 Inhibitors ; Platelet Aggregation Inhibitors ; Cholesterol, HDL ; Phosphoric Diester Hydrolases ; Biology ; Tetrazoles ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 16.

Tytuł:

Effect of multidrug therapy on the prognosis of Mycobacterium avium complex pulmonary disease.

Autorzy:

Ushiki A; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan. .
Tanaka S; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Yamanaka M; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Akahane J; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Ikuyama Y; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Komatsu M; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Sonehara K; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Ichiyama T; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Wada Y; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Tateishi K; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Kitaguchi Y; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
Hanaoka M; First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Feb 23; Vol. 14 (1), pp. 4438. Date of Electronic Publication: 2024 Feb 23.

Typ publikacji:

Journal Article

MeSH Terms:

Mycobacterium avium-intracellulare Infection*/microbiology
Lung Diseases*/microbiology
Humans ; Male ; Middle Aged ; Mycobacterium avium Complex ; Retrospective Studies ; Drug Therapy, Combination ; Leprostatic Agents/pharmacology ; Prognosis

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 17.

Tytuł:

SynerGNet: A Graph Neural Network Model to Predict Anticancer Drug Synergy.

Autorzy:

Liu M; Division of Electrical and Computer Engineering, Louisiana State University, Baton Rouge, LA 70803, USA.
Srivastava G; Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA.
Ramanujam J; Division of Electrical and Computer Engineering, Louisiana State University, Baton Rouge, LA 70803, USA.; Center for Computation and Technology, Louisiana State University, Baton Rouge, LA 70803, USA.
Brylinski M; Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803, USA.; Center for Computation and Technology, Louisiana State University, Baton Rouge, LA 70803, USA.

Pokaż więcej

Źródło:

Biomolecules [Biomolecules] 2024 Feb 21; Vol. 14 (3). Date of Electronic Publication: 2024 Feb 21.

Typ publikacji:

Journal Article

MeSH Terms:

Artificial Intelligence*
Antineoplastic Agents*/pharmacology
Humans ; Neural Networks, Computer ; Combined Modality Therapy ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 18.

Tytuł:

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.

Autorzy:

Semitala FC; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.; Makerere University Joint AIDS Program, Kampala Uganda.
Kadota JL; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Musinguzi A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Welishe F; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakitende A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Akello L; Infectious Diseases Research Collaboration, Kampala, Uganda.
Kunihira Tinka L; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakimuli J; Infectious Diseases Research Collaboration, Kampala, Uganda.
Ritar Kasidi J; Infectious Diseases Research Collaboration, Kampala, Uganda.
Bishop O; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakasendwa S; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
Baik Y; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Patel D; The Better Lab and Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Sammann A; The Better Lab and Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Nahid P; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Belknap R; Denver Health and Hospital Authority and Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado, United States of America.
Kamya MR; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.
Handley MA; Center for Vulnerable Populations, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Phillips PP; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Katahoire A; Child Health and Development Center, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Berger CA; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Kiwanuka N; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
Katamba A; Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
Dowdy DW; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Cattamanchi A; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.; Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Irvine, California, United States of America.

Pokaż więcej

Źródło:

PLoS medicine [PLoS Med] 2024 Feb 20; Vol. 21 (2), pp. e1004356. Date of Electronic Publication: 2024 Feb 20 (Print Publication: 2024).

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

Tuberculosis*/drug therapy
Tuberculosis*/prevention & control
Latent Tuberculosis*/drug therapy
HIV Infections*/complications
HIV Infections*/drug therapy
Rifampin/*analogs & derivatives
Humans ; Isoniazid/adverse effects ; Antitubercular Agents/adverse effects ; Uganda ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 19.

Tytuł:

Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy.

Autorzy:

Sun J; Department of Orthopaedics, The First Affiliated Hospital of Jishou University, The People's Hospital of Xiangxi Autonomous Prefecture, Jishou, China.
Zhang C; Department of Jishou University, Jishou, China.
Su X; Department of Jishou University, Jishou, China.
Zhou H; Department of Medicine, Taizhou University, Zhejiang, China.
Zhou S; Department of Medicine, Taizhou University, Zhejiang, China.
Jiang M; Department of Medicine, Taizhou University, Zhejiang, China.
Fang B; Department of Medicine, Taizhou University, Zhejiang, China. .

Pokaż więcej

Źródło:

Journal of orthopaedic surgery and research [J Orthop Surg Res] 2024 Feb 19; Vol. 19 (1), pp. 147. Date of Electronic Publication: 2024 Feb 19.

Typ publikacji:

Journal Article

MeSH Terms:

Hypertension*/drug therapy
Fibrosarcoma*/drug therapy
Humans ; Antihypertensive Agents/therapeutic use ; Losartan/pharmacology ; Losartan/therapeutic use ; Captopril/pharmacology ; Captopril/therapeutic use ; Spironolactone/therapeutic use ; Furosemide/therapeutic use ; CD8-Positive T-Lymphocytes ; Hydrochlorothiazide/therapeutic use ; Drug Therapy, Combination ; Verapamil/pharmacology ; Verapamil/therapeutic use ; Solute Carrier Family 12, Member 3

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 20.

Tytuł:

Association between failed eradication of 7-day triple therapy for Helicobacter pylori and untreated dental caries in Japanese adults.

Autorzy:

Iwai K; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Azuma T; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Yonenaga T; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Sasai Y; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Watanabe K; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Obora A; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Deguchi F; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Kojima T; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Tomofuji T; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Feb 19; Vol. 14 (1), pp. 4043. Date of Electronic Publication: 2024 Feb 19.

Typ publikacji:

Journal Article

MeSH Terms:

Helicobacter pylori*
Dental Caries*/drug therapy
Helicobacter Infections*/complications
Helicobacter Infections*/drug therapy
Anti-Infective Agents*/therapeutic use
Adult ; Humans ; Anti-Bacterial Agents/therapeutic use ; Cross-Sectional Studies ; Japan/epidemiology ; Drug Therapy, Combination ; Treatment Outcome ; Clarithromycin/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 21.

Tytuł:

Exploring the Roles of Vitamins C and D and Etifoxine in Combination with Citalopram in Depression/Anxiety Model: A Focus on ICAM-1, SIRT1 and Nitric Oxide.

Autorzy:

Gammoh O; Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
Ibrahim A; Faculty of Sciences, Yarmouk University, Irbid 21163, Jordan.
Yehya A; Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
Alqudah A; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan.
Qnais E; Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa 13133, Jordan.
Altaber S; Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa 13133, Jordan.
Alrob OA; Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
Aljabali AAA; Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan.
Tambuwala MM; Lincoln Medical School, Brayford Pool Campus, University of Lincoln, Lincoln LN6 7TS, UK.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2024 Feb 06; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 06.

Typ publikacji:

Journal Article

MeSH Terms:

Anxiety*/drug therapy
Citalopram*/pharmacology
Citalopram*/therapeutic use
Depression*/drug therapy
Nitric Oxide*
Oxazines*/pharmacology
Oxazines*/therapeutic use
Animals ; Mice ; Antidepressive Agents/pharmacology ; Antidepressive Agents/therapeutic use ; Ascorbic Acid/pharmacology ; Ascorbic Acid/therapeutic use ; Intercellular Adhesion Molecule-1 ; Sirtuin 1 ; Vitamin D/pharmacology ; Vitamin D/therapeutic use ; Vitamins ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 22.

Tytuł:

COVID vaccine-induced lupus nephritis: Case report and review of the literature.

Autorzy:

Salas A; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fatola A; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Krimins R; Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kamel IR; Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Geetha D; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fine D; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Monroy-Trujillo M; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rosenberg A; Division of Kidney-Urologic Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Arend L; Division of Kidney-Urologic Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Timlin H; Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA.

Pokaż więcej

Źródło:

Lupus [Lupus] 2024 Feb; Vol. 33 (2), pp. 176-182. Date of Electronic Publication: 2024 Jan 02.

Typ publikacji:

Review; Case Reports; Journal Article

MeSH Terms:

Lupus Nephritis*/drug therapy
COVID-19*
Lupus Erythematosus, Systemic*/chemically induced
Vaccines*
Humans ; Female ; Immunosuppressive Agents/therapeutic use ; COVID-19 Vaccines ; Drug Therapy, Combination ; Mycophenolic Acid/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 23.

Tytuł:

The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.

Autorzy:

Moon JS; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Park IR; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Kim SS; Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Kim HS; Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
Kim NH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul.
Kim SG; Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul.
Ko SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Lee JH; Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Lee I; Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
Lee BK; Clinical Operation Team, Yuhan Corporation, Seoul, Korea.
Won KC; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.

Pokaż więcej

Źródło:

Diabetes & metabolism journal [Diabetes Metab J] 2023 Nov; Vol. 47 (6), pp. 818-825. Date of Electronic Publication: 2023 Nov 24.

Typ publikacji:

Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase IV; Journal Article

MeSH Terms:

Anticholesteremic Agents*/adverse effects
Hypercholesterolemia*
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Cardiovascular Diseases*/epidemiology
Cardiovascular Diseases*/etiology
Cardiovascular Diseases*/prevention & control
Atherosclerosis*/drug therapy
Atherosclerosis*/epidemiology
Humans ; Rosuvastatin Calcium/adverse effects ; Ezetimibe/adverse effects ; Cholesterol, LDL ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 24.

Tytuł:

Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension.

Autorzy:

Moon JS; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Park IR; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Kim HJ; Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
Chung CH; Department of Internal Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea.
Won KC; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Han KA; Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.
Park CY; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Won JC; Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Korea.
Kim DJ; Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea.
Koh GP; Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Korea.
Kim ES; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Yu JM; Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea.
Hong EG; Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
Lee CB; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Yoon KH; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Pokaż więcej

Źródło:

Diabetes & metabolism journal [Diabetes Metab J] 2023 Nov; Vol. 47 (6), pp. 808-817. Date of Electronic Publication: 2023 Sep 26.

Typ publikacji:

Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III; Journal Article

MeSH Terms:

Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/chemically induced
Metformin*/adverse effects
Humans ; Hypoglycemic Agents/adverse effects ; Glycated Hemoglobin ; Drug Therapy, Combination ; Glucose

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 25.

Tytuł:

Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy.

Autorzy:

de Araujo ACGDS; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (INI/Fiocruz), Rio de Janeiro, RJ, Brazil.
Hacker MAV; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
Pinheiro RO; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
Illarramendi X; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
Durães SMB; Dermatology Department, Fluminense Federal University (UFF), Niterói, RJ, Brazil.
Nobre ML; Giselda Trigueiro Hospital, Rio Grande do Norte Federal State Public Health department (SESAP-RN), Natal, RN, Brazil.
Moraes MO; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
Sales AM; Oswaldo Cruz Institute, Oswaldo Cruz Foundation (IOC/Fiocruz), Rio de Janeiro, RJ, Brazil.
da Silva GMS; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation (INI/Fiocruz), Rio de Janeiro, RJ, Brazil.

Pokaż więcej

Źródło:

PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2024 Jan 25; Vol. 18 (1), pp. e0011901. Date of Electronic Publication: 2024 Jan 25 (Print Publication: 2024).

Typ publikacji:

Journal Article

MeSH Terms:

Leprosy*/drug therapy
Drug-Related Side Effects and Adverse Reactions*
Adult ; Humans ; Female ; Dapsone/adverse effects ; Leprostatic Agents/adverse effects ; Rifampin/therapeutic use ; Drug Therapy, Combination ; Case-Control Studies ; Clofazimine/therapeutic use ; Brazil/epidemiology ; World Health Organization

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 26.

Tytuł:

Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.

Autorzy:

Dawson R; Division of Pulmonology, Department of Medicine, University of Cape Town and University of Cape Town Lung Institute, Cape Town, South Africa.
Diacon AH; Department of Medicine, Stellenbosch University, Cape Town, South Africa.; TASK Applied Science, Cape Town, South Africa.
Takuva S; Otsuka Novel Products GmbH, Munich, Germany.; Faculty of Health Sciences, School of Health Systems and Public Health, University of Pretoria, Pretoria, South Africa.
Liu Y; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.
Zheng B; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.
Karwe V; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.
Hafkin J; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA. .

Pokaż więcej

Źródło:

Trials [Trials] 2024 Jan 19; Vol. 25 (1), pp. 70. Date of Electronic Publication: 2024 Jan 19.

Typ publikacji:

Clinical Trial Protocol; Journal Article

MeSH Terms:

Diarylquinolines*
HIV Infections*/drug therapy
Nitroimidazoles*
Oxazoles*
Tuberculosis, Multidrug-Resistant*/diagnosis
Tuberculosis, Pulmonary*/diagnosis
Tuberculosis, Pulmonary*/drug therapy
Tuberculosis, Pulmonary*/microbiology
Humans ; Antitubercular Agents ; Clinical Trials, Phase II as Topic ; Drug Therapy, Combination ; Multicenter Studies as Topic ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 27.

Tytuł:

An Overview of Advances in Rare Cancer Diagnosis and Treatment.

Autorzy:

Christyani G; Department of Integrated Biomedical Science, Soonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, Cheonan 31151, Chungcheongnam-do, Republic of Korea.
Carswell M; Department of Integrated Biomedical Science, Soonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, Cheonan 31151, Chungcheongnam-do, Republic of Korea.
Qin S; Department of Integrated Biomedical Science, Soonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, Cheonan 31151, Chungcheongnam-do, Republic of Korea.
Kim W; Department of Integrated Biomedical Science, Soonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, Cheonan 31151, Chungcheongnam-do, Republic of Korea.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2024 Jan 18; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 18.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Artificial Intelligence*
Neoplasms*/diagnosis
Neoplasms*/therapy
Humans ; Drug Therapy, Combination ; Immunotherapy ; Drug Development

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 28.

Tytuł:

Augmented drug combination dataset to improve the performance of machine learning models predicting synergistic anticancer effects.

Autorzy:

Liu M; Division of Electrical and Computer Engineering, Louisiana State University, Baton Rouge, LA, 70803, USA.
Srivastava G; Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, 70803, USA.
Ramanujam J; Division of Electrical and Computer Engineering, Louisiana State University, Baton Rouge, LA, 70803, USA.; Center for Computation and Technology, Louisiana State University, Baton Rouge, LA, 70803, USA.
Brylinski M; Department of Biological Sciences, Louisiana State University, Baton Rouge, LA, 70803, USA. .; Center for Computation and Technology, Louisiana State University, Baton Rouge, LA, 70803, USA. .

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Jan 18; Vol. 14 (1), pp. 1668. Date of Electronic Publication: 2024 Jan 18.

Typ publikacji:

Journal Article

MeSH Terms:

Computational Biology*/methods
Machine Learning*
Drug Synergism ; Drug Combinations ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 29.

Tytuł:

Triple artemisinin-based combination therapy (TACT): advancing malaria control and eradication efforts.

Autorzy:

Kokori E; Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara, Nigeria.
Olatunji G; Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara, Nigeria.
Akinboade A; Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara, Nigeria.
Akinoso A; Department of Medicine and Surgery, University of Ilorin, Ilorin, Kwara, Nigeria.
Egbunu E; Federal Medical Centre, Bida, Niger, Nigeria.
Aremu SA; Lagos University Teaching Hospital, Lagos, Nigeria.
Okafor CE; Afe Babalola University, Ado Ekiti, Nigeria.
Oluwole O; Lagos University Teaching Hospital, Lagos, Nigeria.
Aderinto N; Department of Medicine, Ladoke Akintola University of Technology, Ogbomosho, Nigeria. .

Pokaż więcej

Źródło:

Malaria journal [Malar J] 2024 Jan 18; Vol. 23 (1), pp. 25. Date of Electronic Publication: 2024 Jan 18.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Antimalarials*/therapeutic use
Malaria*/drug therapy
Malaria*/prevention & control
Artemisinins*/therapeutic use
Humans ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 30.

Tytuł:

Resistance to Combined Anthracycline-Taxane Chemotherapy Is Associated with Altered Metabolism and Inflammation in Breast Carcinomas.

Autorzy:

Menyhárt O; Oncology Biomarker Research Group, Institute of Molecular Life Sciences, Hungarian Research Network, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary.; National Laboratory for Drug Research and Development, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary.; Department of Bioinformatics, Semmelweis University, 1094 Budapest, Hungary.
Fekete JT; Oncology Biomarker Research Group, Institute of Molecular Life Sciences, Hungarian Research Network, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary.; National Laboratory for Drug Research and Development, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary.; Department of Bioinformatics, Semmelweis University, 1094 Budapest, Hungary.
Győrffy B; Oncology Biomarker Research Group, Institute of Molecular Life Sciences, Hungarian Research Network, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary.; National Laboratory for Drug Research and Development, Magyar Tudósok Körútja 2, 1117 Budapest, Hungary.; Department of Bioinformatics, Semmelweis University, 1094 Budapest, Hungary.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2024 Jan 15; Vol. 25 (2). Date of Electronic Publication: 2024 Jan 15.

Typ publikacji:

Journal Article

MeSH Terms:

Anthracyclines*/therapeutic use
Inflammatory Breast Neoplasms*
Bridged-Ring Compounds*
Taxoids*
Humans ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Drug Therapy, Combination ; Antibiotics, Antineoplastic ; Inflammation/genetics ; Tumor Microenvironment

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 31.

Tytuł:

Efficacy of a 2-week therapy with levofloxacin concomitant versus a levofloxacin sequential regimen for Helicobacter pylori infection in the Syrian population: a study protocol for randomized controlled trial.

Autorzy:

Alhalabi M; Gastroenterology Department, Damascus Hospital, Almujtahed Street, Damascus, Syria. .
Almokdad R; Gastroenterology Department, Damascus Hospital, Almujtahed Street, Damascus, Syria.

Pokaż więcej

Źródło:

Trials [Trials] 2024 Jan 15; Vol. 25 (1), pp. 55. Date of Electronic Publication: 2024 Jan 15.

Typ publikacji:

Clinical Trial Protocol; Journal Article

MeSH Terms:

Helicobacter Infections*/diagnosis
Helicobacter Infections*/drug therapy
Helicobacter pylori*
Adolescent ; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Anti-Bacterial Agents/adverse effects ; Clinical Protocols ; Drug Therapy, Combination ; Levofloxacin/adverse effects ; Metronidazole ; Prospective Studies ; Proton Pump Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Syria ; Treatment Outcome ; Equivalence Trials as Topic

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 32.

Tytuł:

A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study).

Autorzy:

Kim HJ; Department of Endocrinology & Metabolism, Ajou University School of Medicine, Suwon, Republic of Korea.
Noh JH; Division of Endocrinology and Metabolism, Department of Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Republic of Korea.
Moon MK; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea.
Choi SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Ko SH; Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Rhee EJ; Department of Endocrinology and Metabolism, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Hur KY; Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Jeong IK; Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Republic of Korea.

Pokaż więcej

Źródło:

Journal of diabetes research [J Diabetes Res] 2024 Jan 05; Vol. 2024, pp. 8915591. Date of Electronic Publication: 2024 Jan 05 (Print Publication: 2024).

Typ publikacji:

Randomized Controlled Trial; Multicenter Study; Journal Article

MeSH Terms:

Diabetes Mellitus, Type 2*/drug therapy
Metformin*/administration & dosage
Piperidones*
Pyrimidines*
Sodium-Glucose Transporter 2 Inhibitors*/therapeutic use
Humans ; Blood Glucose ; Double-Blind Method ; Drug Therapy, Combination ; Glycated Hemoglobin ; Glycemic Control ; Hypoglycemic Agents/administration & dosage ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 33.

Tytuł:

LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study.

Autorzy:

Katzmann JL; Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany. .
Stürzebecher PE; Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany.
Kruppert S; IQVIA Germany, Frankfurt am Main, Germany.
Laufs U; Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Leipzig, Germany.

Pokaż więcej

Źródło:

Scientific reports [Sci Rep] 2024 Jan 04; Vol. 14 (1), pp. 474. Date of Electronic Publication: 2024 Jan 04.

Typ publikacji:

Journal Article

MeSH Terms:

Hydroxymethylglutaryl-CoA Reductase Inhibitors*/adverse effects
Anticholesteremic Agents*
Humans ; Cholesterol, LDL ; Drug Therapy, Combination ; Ezetimibe/therapeutic use ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 34.

Tytuł:

Factors influencing patients' adherence to malaria artemisinin-based combination therapy in Kamuli District, Uganda.

Autorzy:

Bawate C; Kamuli General Hospital-Kamuli District Local Government, Kamuli, Uganda. .
Callender-Carter ST; Bugema University, Kampala, Uganda.
Guyah B; School of Public Health and Community Development, Maseno University, Maseno, Kenya.
Ouma C; School of Public Health and Community Development, Maseno University, Maseno, Kenya.

Pokaż więcej

Źródło:

Malaria journal [Malar J] 2024 Jan 02; Vol. 23 (1), pp. 1. Date of Electronic Publication: 2024 Jan 02.

Typ publikacji:

Journal Article

MeSH Terms:

Artemisinins*/therapeutic use
Malaria*/drug therapy
Malaria*/prevention & control
Malaria*/epidemiology
Antimalarials*/therapeutic use
Female ; Humans ; Young Adult ; Adult ; Male ; Uganda ; Longitudinal Studies ; Drug Combinations ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 35.

Tytuł:

Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases.

Autorzy:

Welzel T; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland. .; Division of Pediatric Rheumatology, Department of Pediatrics and Autoinflammation Reference Centre Tuebingen (arcT), University Hospital Tuebingen, Tuebingen, Germany. .; Pediatric Rheumatology, University Children's Hospital Basel, University of Basel, Basel, Switzerland. .; Pediatric Research Center, University Children's Hospital Basel, University of Basel, Basel, Switzerland. .
Golhen K; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Atkinson A; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.; Pediatric Research Center, University Children's Hospital Basel, University of Basel, Basel, Switzerland.; Division of Infectious Diseases, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Gotta V; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Ternant D; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.; Université de Tours, service de pharmacologie médicale, Tours France, Université de Tours, EA 4245 T2I, Tours, France.
Kuemmerle-Deschner JB; Division of Pediatric Rheumatology, Department of Pediatrics and Autoinflammation Reference Centre Tuebingen (arcT), University Hospital Tuebingen, Tuebingen, Germany.
Michler C; Division of Pediatric Rheumatology, Department of Pediatrics and Autoinflammation Reference Centre Tuebingen (arcT), University Hospital Tuebingen, Tuebingen, Germany.
Koch G; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
van den Anker JN; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Pfister M; Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Woerner A; Pediatric Rheumatology, University Children's Hospital Basel, University of Basel, Basel, Switzerland.

Pokaż więcej

Źródło:

Pediatric rheumatology online journal [Pediatr Rheumatol Online J] 2024 Jan 02; Vol. 22 (1), pp. 5. Date of Electronic Publication: 2024 Jan 02.

Typ publikacji:

Journal Article

MeSH Terms:

Antirheumatic Agents*/adverse effects
Arthritis, Rheumatoid*/drug therapy
Female ; Humans ; Child ; Adalimumab/adverse effects ; Methotrexate/adverse effects ; Prospective Studies ; Antibodies, Monoclonal, Humanized/therapeutic use ; Treatment Outcome ; Drug Therapy, Combination

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 36.

Tytuł:

Effectiveness and safety of immunosuppressive regimens used as maintenance therapy in kidney transplantation: The CESIT study.

Autorzy:

Bellini A; Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Finocchietti M; Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Rosa AC; Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Nordio M; Azienda Zero of the Veneto Region, Padua, Italy.
Ferroni E; Azienda Zero of the Veneto Region, Padua, Italy.
Massari M; National Centre for Drug Research and Evaluation, Istituto Superiore Di Sanità, Rome, Italy.
Spila Alegiani S; National Centre for Drug Research and Evaluation, Istituto Superiore Di Sanità, Rome, Italy.
Masiero L; Italian National Transplant Centre, Istituto Superiore di Sanità, Rome, Italy.
Bedeschi G; Italian National Transplant Centre, Istituto Superiore di Sanità, Rome, Italy.
Cardillo M; Italian National Transplant Centre, Istituto Superiore di Sanità, Rome, Italy.
Lucenteforte E; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Piccolo G; Regional Transplant Coordination, Lombardy Region, Milan, Italy.
Leoni O; Department of Health of Lombardy Region, Epidemiology Observatory, Milan, Italy.
Pierobon S; Azienda Zero of the Veneto Region, Padua, Italy.
Ledda S; General Directorate for Health, Sardinia Region, Italy.
Garau D; General Directorate for Health, Sardinia Region, Italy.
Davoli M; Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Addis A; Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.
Belleudi V; Department of Epidemiology, Lazio Regional Health Service, Rome, Italy.

Pokaż więcej

Corporate Authors:

CESIT study group

Źródło:

PloS one [PLoS One] 2024 Jan 02; Vol. 19 (1), pp. e0295205. Date of Electronic Publication: 2024 Jan 02 (Print Publication: 2024).

Typ publikacji:

Multicenter Study; Observational Study; Journal Article

MeSH Terms:

Immunosuppressive Agents*/adverse effects
Kidney Transplantation*
Humans ; Cyclosporine/adverse effects ; Diabetes Mellitus/epidemiology ; Drug Therapy, Combination ; Mycophenolic Acid/adverse effects ; Tacrolimus/adverse effects

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 37.

Tytuł:

Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus.

Autorzy:

Han JH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Joung KH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Division of Endocrinology and Metabolism, Department of International Medicine, Chungnam National University Sejong Hospital, Sejong, Korea.
Lee JC; Division of Endocrinology and Metabolism, Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea.
Kim OS; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Choung S; Department of Medical Science, Chungnam National University College of Medicine, Daejeon, Korea.
Kim JM; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Division of Endocrinology and Metabolism, Department of International Medicine, Chungnam National University Sejong Hospital, Sejong, Korea.
Kang YE; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Yi HS; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.; Laboratory of Endocrinology and Immune System, Chungnam National University College of Medicine, Daejeon, Korea.
Lee JH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Ku BJ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Kim HJ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.

Pokaż więcej

Źródło:

Diabetes & metabolism journal [Diabetes Metab J] 2024 Jan; Vol. 48 (1), pp. 112-121. Date of Electronic Publication: 2024 Jan 03.

Typ publikacji:

Comparative Study; Journal Article; Randomized Controlled Trial

MeSH Terms:

Anticholesteremic Agents*/therapeutic use
Diabetes Mellitus, Type 2*/drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors*/therapeutic use
Insulin Resistance*
Humans ; Cholesterol, LDL ; Drug Therapy, Combination ; Ezetimibe/therapeutic use ; Rosuvastatin Calcium/therapeutic use ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 38.

Tytuł:

Efficacy comparison of 7- and 14-day P-CAB based bismuth-containing quadruple regimen with PPI based bismuth-containing quadruple regimen for Helicobacter pylori infection: rationale and design of an open-label, multicenter, randomized controlled trial.

Autorzy:

Oh CK; Department of Internal Medicine, Gangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeoungdeungpo-gu, Seoul, 07441, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Lim H; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, 22 Gwanpyeong-ro 170-gil, Dongan-gu, Anyang, 14068, Korea. .; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea. .
Seo SI; Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150 Seongan-ro, Gangdong-gu, Seoul, 05355, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Lee SP; Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, 7 Keunjaebong-gil, Hwaseong, 18450, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Bang CS; Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, 77 Sakju-ro, Chuncheon, 24253, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Shin WG; Department of Internal Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, 150 Seongan-ro, Gangdong-gu, Seoul, 05355, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Kim JB; Department of Internal Medicine, Gangnam Sacred Heart Hospital, Hallym University College of Medicine, 1 Singil-ro, Yeoungdeungpo-gu, Seoul, 07441, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Jang HJ; Department of Internal Medicine, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, 7 Keunjaebong-gil, Hwaseong, 18450, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.
Baik GH; Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, 77 Sakju-ro, Chuncheon, 24253, Korea.; Institute for Liver and Digestive Diseases, Hallym University, 1 Hallymdaehak-gil, Chuncheon, 24252, Korea.

Pokaż więcej

Źródło:

BMC gastroenterology [BMC Gastroenterol] 2023 Dec 21; Vol. 23 (1), pp. 453. Date of Electronic Publication: 2023 Dec 21.

Typ publikacji:

Clinical Trial Protocol; Journal Article

MeSH Terms:

Helicobacter Infections*/drug therapy
Helicobacter pylori*
Humans ; Amoxicillin/therapeutic use ; Amoxicillin/adverse effects ; Anti-Bacterial Agents/adverse effects ; Bismuth/therapeutic use ; Drug Therapy, Combination ; Metronidazole/therapeutic use ; Multicenter Studies as Topic ; Proton Pump Inhibitors/therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome ; Research Design

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 39.

Tytuł:

Fertility Protection, A Novel Concept: Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Protect against Chemotherapy-Induced Testicular Cytotoxicity.

Autorzy:

Liakath Ali F; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Park HS; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Beckman A; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Eddy AC; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Alkhrait S; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Ghasroldasht MM; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Al-Hendy A; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.
Raheem O; Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL 60637, USA.; Department of Surgery, University of Chicago, Chicago, IL 60637, USA.

Pokaż więcej

Źródło:

International journal of molecular sciences [Int J Mol Sci] 2023 Dec 20; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 20.

Typ publikacji:

Journal Article

MeSH Terms:

Exosomes*
Mesenchymal Stem Cells*
Male ; Humans ; Animals ; Mice ; Drug Therapy, Combination ; Fertility ; Spermatogonia

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 40.

Tytuł:

Combination Drug Therapy for the Management of Chronic Neuropathic Pain.

Autorzy:

Boccella S; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via De Amicis, 80131 Naples, Italy.
De Filippis L; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, Italy.
Giorgio C; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via De Amicis, 80131 Naples, Italy.
Brandolini L; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via Campo di Pile, 67100 L'Aquila, Italy.
Jones M; Research & Early Development (R&D), Dompé US, 181 2nd Avenue, STE 600, San Mateo, CA 94401, USA.
Novelli R; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, Italy.
Amorizzo E; Pain Unit, San Paolo Hospital, 00053 Civitavecchia, Italy.; Pain Clinic Roma, 00191 Rome, Italy.
Leoni MLG; Azienda USL di Piacenza, 29121 Piacenza, Italy.; Department of Medical and Surgical Sciences and Translational Medicine, Sapienza University, 00185 Rome, Italy.
Terranova G; Pain Unit, ASST Gaetano Pini, 20122 Milan, Italy.
Maione S; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', 80138 Naples, Italy.
Luongo L; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', 80138 Naples, Italy.
Leone M; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, Italy.
Allegretti M; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via Campo di Pile, 67100 L'Aquila, Italy.
Minnella EM; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via S. Lucia, 20122 Milan, Italy.
Aramini A; Research & Early Development (R&D), Dompé Farmaceutici S.p.A, Via Campo di Pile, 67100 L'Aquila, Italy.

Pokaż więcej

Źródło:

Biomolecules [Biomolecules] 2023 Dec 16; Vol. 13 (12). Date of Electronic Publication: 2023 Dec 16.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Neuralgia*/drug therapy
Humans ; Drug Therapy, Combination ; Combined Modality Therapy

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 41.

Tytuł:

The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials.

Autorzy:

Liu LH; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China. .
Han B; Department of Endoscopy, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China.
Tao J; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China.
Zhang K; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China.
Wang XK; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, Guizhou provincial people's hospital, Guiyang, Guizhou Province, China.
Wang WY; Department of Pediatric Gastroenterology, Guizhou Branch of Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine, 395 Jinzhu East Road, Guanshanhu District, Guiyang City, Guizhou Province, China. .

Pokaż więcej

Źródło:

BMC infectious diseases [BMC Infect Dis] 2023 Dec 15; Vol. 23 (1), pp. 878. Date of Electronic Publication: 2023 Dec 15.

Typ publikacji:

Meta-Analysis; Systematic Review; Journal Article

MeSH Terms:

Saccharomyces boulardii*
Helicobacter pylori*
Helicobacter Infections*/drug therapy
Helicobacter Infections*/prevention & control
Probiotics*/therapeutic use
Child ; Humans ; Drug Therapy, Combination ; Randomized Controlled Trials as Topic ; Abdominal Pain/drug therapy ; Dietary Supplements ; Anti-Bacterial Agents/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 42.

Tytuł:

BMC3PM: bioinformatics multidrug combination protocol for personalized precision medicine and its application in cancer treatment.

Autorzy:

Mokhtari M; Department of Bioinformatics, Kish International Campus, University of Tehran, Kish Island, Iran. .
Khoshbakht S; Department of Bioinformatics, Kish International Campus, University of Tehran, Kish Island, Iran.; Duke Molecular Physiology Institute, Duke University School of Medicine-Cardiology, Durham, NC, 27701, USA.
Akbari ME; Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Moravveji SS; Department of Bioinformatics, Kish International Campus, University of Tehran, Kish Island, Iran.

Pokaż więcej

Źródło:

BMC medical genomics [BMC Med Genomics] 2023 Dec 12; Vol. 16 (1), pp. 328. Date of Electronic Publication: 2023 Dec 12.

Typ publikacji:

Journal Article

MeSH Terms:

Precision Medicine*/methods
Neoplasms*/drug therapy
Neoplasms*/genetics
Humans ; Computational Biology ; Drug Therapy, Combination ; Drug Combinations

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 43.

Tytuł:

Association of PTX3 gene polymorphisms and PTX3 plasma levels with leprosy susceptibility.

Autorzy:

Moraes ACCG; Postgraduate Program in Health and Biological Sciences, Federal University of the São Francisco Valley (UNIVASF), Pernambuco, Brazil.
da Luz RCFV; Postgraduate Program in Health and Biological Sciences, Federal University of the São Francisco Valley (UNIVASF), Pernambuco, Brazil.
Fernandes ALM; Foundation of Hematology and Hemotherapy of Bahia (HEMOBA), Bahia, Brazil.
Barbosa MXS; Postgraduate Program in Biosciences, Federal University of the São Francisco Valley (UNIVASF), Pernambuco, Brazil.
de Andrade LV; Postgraduate Program in Biosciences, Federal University of the São Francisco Valley (UNIVASF), Pernambuco, Brazil.
Armstrong ADC; College of Medicine, Federal University of the São Francisco Valley (UNIVASF), Av. José de Sá Maniçoba, s/n, Centro, Petrolina, PE, Brazil.
de Souza CDF; College of Medicine, Federal University of the São Francisco Valley (UNIVASF), Av. José de Sá Maniçoba, s/n, Centro, Petrolina, PE, Brazil.
do Carmo RF; Postgraduate Program in Health and Biological Sciences, Federal University of the São Francisco Valley (UNIVASF), Pernambuco, Brazil. .; Postgraduate Program in Biosciences, Federal University of the São Francisco Valley (UNIVASF), Pernambuco, Brazil. .; College of Medicine, Federal University of the São Francisco Valley (UNIVASF), Av. José de Sá Maniçoba, s/n, Centro, Petrolina, PE, Brazil. .

Pokaż więcej

Źródło:

BMC infectious diseases [BMC Infect Dis] 2023 Dec 05; Vol. 23 (1), pp. 853. Date of Electronic Publication: 2023 Dec 05.

Typ publikacji:

Journal Article

MeSH Terms:

Leprostatic Agents*
Leprosy*/genetics
Humans ; Drug Therapy, Combination ; C-Reactive Protein/genetics ; C-Reactive Protein/analysis ; Biomarkers ; Polymorphism, Single Nucleotide

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 44.

Tytuł:

Age and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: a post hoc analysis of the randomized PATH-PCI trial.

Autorzy:

Pan Y; Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Urumqi, China.
Wu TT; Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Urumqi, China.
Hou XG; Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Urumqi, China.
Yang Y; Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Urumqi, China.
Deng CJ; Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Urumqi, China.
Wang S; Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Urumqi, China.
Zheng YY; Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Urumqi, China.
Xie X; Department of Cardiology, Xinjiang Medical University Affiliated First Hospital, Urumqi, China.

Pokaż więcej

Źródło:

Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2206915.

Typ publikacji:

Journal Article; Randomized Controlled Trial

MeSH Terms:

Acute Coronary Syndrome*/therapy
Percutaneous Coronary Intervention*/adverse effects
Humans ; Drug Therapy, Combination ; Dual Anti-Platelet Therapy ; Hemorrhage/drug therapy ; Platelet Aggregation Inhibitors/pharmacology ; Platelet Aggregation Inhibitors/therapeutic use ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 45.

Tytuł:

Tailoring antiplatelet therapy in older patients with coronary artery disease.

Autorzy:

Kovacevic M; Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia.
Pompei G; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK and.
Kunadian V; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK and.; Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Pokaż więcej

Źródło:

Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2285446. Date of Electronic Publication: 2023 Dec 05.

Typ publikacji:

Journal Article; Review

MeSH Terms:

Coronary Artery Disease*/complications
Percutaneous Coronary Intervention*/adverse effects
Acute Coronary Syndrome*/drug therapy
Humans ; Aged ; Platelet Aggregation Inhibitors/adverse effects ; Aspirin/therapeutic use ; Dual Anti-Platelet Therapy/methods ; Hemorrhage/drug therapy ; Drug Therapy, Combination ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 46.

Tytuł:

Efficacy of spironolactone as adjunctive therapy to sodium valproate in bipolar-I disorder: A double-blind, randomized, placebo-controlled clinical trial.

Autorzy:

Zandifar A; Social Determinants of Health Research Center, Alborz University of Medical Sciences, Karaj, Iran.; Department of Psychiatry, Imam Hossein Hospital, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Badrfam R; Department of Psychiatry, Imam Hossein Hospital, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Gholamian F; School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Shafiee A; Clinical Research Development Unit, Alborz University of Medical Sciences, Karaj, Iran.; Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Pokaż więcej

Źródło:

Brain and behavior [Brain Behav] 2023 Dec; Vol. 13 (12), pp. e3313. Date of Electronic Publication: 2023 Nov 06.

Typ publikacji:

Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

MeSH Terms:

Bipolar Disorder*/diagnosis
Humans ; Double-Blind Method ; Drug Therapy, Combination ; Mania/drug therapy ; Psychiatric Status Rating Scales ; Spironolactone/therapeutic use ; Treatment Outcome ; Valproic Acid/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 47.

Tytuł:

Is the combination of linagliptin and allopurinol better prophylaxis against post-contrast acute kidney injury? A multicenter prospective randomized controlled study.

Autorzy:

Fayed A; Nephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Giza, Egypt.
Hammad AA; Endocrinology Unit, Internal Medicine Department, Faculty of Medicine, Fayoum University, Faiyum, Egypt.
Abdulazim DO; Rheumatology and Rehabilitation Department, Kasr Alainy School of Medicine, Cairo University, Giza, Egypt.
Hammad H; Nephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Giza, Egypt.
Amin M; Critical Care Medicine Department, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Giza, Egypt.
Elhadidy S; Critical Care Medicine Department, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Giza, Egypt.
Salem MM; Endocrinology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Giza, Egypt.
ElAzim IMA; Critical Care Medicine, Theodor Bilharz Research Institute, Cairo, Egypt.
Zsom L; Fresenius Medical Care Hungary, Cegléd, Hungary.
Csongradi E; Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Soliman KM; Department of Surgery, Division of Transplant, Medical University of South Carolina, Charleston, SC, USA.
Sharaf El Din UA; Nephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Giza, Egypt.

Pokaż więcej

Źródło:

Renal failure [Ren Fail] 2023 Dec; Vol. 45 (1), pp. 2194434.

Typ publikacji:

Randomized Controlled Trial; Multicenter Study; Journal Article

MeSH Terms:

Acute Kidney Injury*/chemically induced
Acute Kidney Injury*/etiology
Acute Kidney Injury*/prevention & control
Allopurinol*/administration & dosage
Allopurinol*/therapeutic use
Diabetic Nephropathies*/classification
Diabetic Nephropathies*/complications
Diabetic Nephropathies*/diagnosis
Linagliptin*/administration & dosage
Linagliptin*/therapeutic use
Contrast Media*/adverse effects
Protective Agents*/administration & dosage
Protective Agents*/adverse effects
Protective Agents*/therapeutic use
Humans ; Kidney Failure, Chronic/complications ; Kidney Failure, Chronic/diagnosis ; Prospective Studies ; Renal Insufficiency, Chronic/classification ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/diagnosis ; Chemoprevention/methods ; Drug Therapy, Combination ; Acetylcysteine/administration & dosage ; Acetylcysteine/therapeutic use ; Saline Solution/administration & dosage ; Saline Solution/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 48.

Tytuł:

Tenofovir alafenamide plus dolutegravir as a switch strategy in HIV-infected patients: a pilot randomized controlled trial.

Autorzy:

Alavian G; Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Abbasian L; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. .; Department of Infectious & Tropical Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Keshavarz Blvd, Tehran, Iran. .
Khalili H; Department of Clinical Pharmacy (Pharmacotherapy), Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Alinaghi SAS; Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Hasannezhad M; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Ashtiani MF; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Manshadi SAD; Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran.

Pokaż więcej

Źródło:

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences [Daru] 2023 Dec; Vol. 31 (2), pp. 145-153. Date of Electronic Publication: 2023 Aug 04.

Typ publikacji:

Randomized Controlled Trial; Journal Article

MeSH Terms:

HIV Infections*/drug therapy
Drug-Related Side Effects and Adverse Reactions*/drug therapy
Anti-HIV Agents*/therapeutic use
Anti-HIV Agents*/adverse effects
Humans ; Tenofovir/adverse effects ; Emtricitabine/adverse effects ; Pilot Projects ; Treatment Outcome ; Adenine ; Drug Therapy, Combination ; RNA/therapeutic use

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknieSzczegóły

Skocz do pozycji: 49.

Tytuł:

Sex differences in antiplatelet therapy: state-of-the art.

Autorzy:

Gasecka A; 1st Chair and Department of Cardiology, Medical University of Warsaw, Independent Public Central Teaching Hospital, Warsaw, Poland.
Zimodro JM; 1st Chair and Department of Cardiology, Medical University of Warsaw, Independent Public Central Teaching Hospital, Warsaw, Poland.
Appelman Y; Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, VU University, Amsterdam, The Netherlands.

Pokaż więcej

Źródło:

Platelets [Platelets] 2023 Dec; Vol. 34 (1), pp. 2176173. Date of Electronic Publication: 2023 Feb 21.

Typ publikacji:

Review; Journal Article

MeSH Terms:

Percutaneous Coronary Intervention*
Acute Coronary Syndrome*/drug therapy
Female ; Humans ; Male ; Platelet Aggregation Inhibitors/pharmacology ; Platelet Aggregation Inhibitors/therapeutic use ; Sex Factors ; Sex Characteristics ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Drug Therapy, Combination ; Treatment Outcome

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły

Skocz do pozycji: 50.

Tytuł:

Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial).

Autorzy:

Aumpan N; Center of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Thammasat University, Pathumthani, Thailand.; Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University, Pathumthani, Thailand.
Issariyakulkarn N; Center of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Thammasat University, Pathumthani, Thailand.
Mahachai V; Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University, Pathumthani, Thailand.
Graham D; Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America.
Yamaoka Y; Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, Houston, Texas, United States of America.; Department of Environmental and Preventive Medicine, Oita University Faculty of Medicine, Yufu, Japan.; Research Center for Global and Local Infectious Diseases, Oita University, Yufu, Japan.
Vilaichone RK; Center of Excellence in Digestive Diseases and Gastroenterology Unit, Department of Medicine, Thammasat University, Pathumthani, Thailand.; Department of Medicine, Chulabhorn International College of Medicine (CICM) at Thammasat University, Pathumthani, Thailand.

Pokaż więcej

Źródło:

PloS one [PLoS One] 2023 Nov 30; Vol. 18 (11), pp. e0294403. Date of Electronic Publication: 2023 Nov 30 (Print Publication: 2023).

Typ publikacji:

Clinical Trial; Journal Article

MeSH Terms:

Helicobacter Infections*/drug therapy
Helicobacter Infections*/diagnosis
Helicobacter pylori*
Female ; Humans ; Male ; Middle Aged ; Amoxicillin/therapeutic use ; Anti-Bacterial Agents/therapeutic use ; Clarithromycin/therapeutic use ; Drug Therapy, Combination ; Levofloxacin/therapeutic use ; Metronidazole/therapeutic use ; Retrospective Studies ; Treatment Failure

Czasopismo naukowe

• na półce

Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły